Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, Philippines.
Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, Philippines.
Transplant Proc. 2024 Apr;56(3):540-545. doi: 10.1016/j.transproceed.2023.11.034. Epub 2024 Feb 27.
The COVID-19 pandemic significantly lowered kidney transplantation (KT) rates worldwide, and studies regarding outcomes of patients who developed COVID-19 infection before KT are limited, especially in low to middle-income countries.
To determine the 1-year graft and patient survival of kidney transplant recipients who recovered from COVID-19 infection before KT.
We retrospectively reviewed all adult end-stage renal disease patients who underwent KT at the National Kidney and Transplant Institute from June 2020 through October 2021. Transplant parameters, graft and patient survival, pretransplant COVID-19 infection, and post-KT infectious complications were recorded. Data was analyzed using two-tailed descriptive statistical tests.
Of the 219 recipients, 23 (11%) had COVID-19 infection within 1 to 16 months before KT. The mean age of KT recipients was 36 years (range, 25-57), and 61.9% had chronic glomerulonephritis as primary renal disease. The mean duration from COVID-19 recovery to KT was 79 days (range, 21-207). There was no significant difference in the 1-year biopsy-proven acute rejection in the 2 groups, at 4.5% vs 12.5% for the COVID-19 and non-COVID-19 group, respectively. Both the 1-year graft and patient survival were similar in the COVID-19 and non-COVID-19 groups at 98.4% vs 100% and 100% vs 98.44%, respectively.
There was no significant difference in biopsy-proven acute rejection, 1-year graft, and patient survival among patients who had a prior COVID-19 infection vs those who did not. Kidney transplantation appears safe when performed at least 1 month from COVID-19 infection.
COVID-19 大流行使全球范围内的肾脏移植(KT)率显著降低,关于在 KT 前感染 COVID-19 的患者结局的研究有限,尤其是在中低收入国家。
确定从 KT 前 COVID-19 感染中康复的肾移植受者的 1 年移植物和患者存活率。
我们回顾性审查了 2020 年 6 月至 2021 年 10 月期间在国立肾脏和移植研究所接受 KT 的所有成年终末期肾病患者。记录了移植参数、移植物和患者存活率、移植前 COVID-19 感染和 KT 后感染性并发症。使用双尾描述性统计检验分析数据。
在 219 名受者中,有 23 名(11%)在 KT 前 1 至 16 个月内感染 COVID-19。KT 受者的平均年龄为 36 岁(范围 25-57 岁),61.9%的患者原发性肾病为慢性肾小球肾炎。从 COVID-19 康复到 KT 的平均时间为 79 天(范围 21-207 天)。在两组中,1 年活检证实的急性排斥反应无显著差异,COVID-19 组为 4.5%,非 COVID-19 组为 12.5%。COVID-19 组和非 COVID-19 组的 1 年移植物和患者存活率分别为 98.4%对 100%和 100%对 98.44%,也相似。
在有或没有先前 COVID-19 感染的患者中,活检证实的急性排斥反应、1 年移植物和患者存活率无显著差异。至少在 COVID-19 感染后 1 个月进行 KT 似乎是安全的。